The corporate strength of Kaijie Bioengineering (Shenzhen) Co., Ltd.

The company has established a fully closed automated production process and a strict quality control management system in accordance with GMP requirements, and has an annual production capacity of 30 million fluorescent PCR detection reagents. Kaijie Bioengineering (Shenzhen) Co., Ltd. has a large number of professionals and is the manufacturer that has obtained the most product production approval numbers in this industry in China. Many of the company's achievements have been reviewed by national experts, and its products will be gradually introduced to the market.

In 2005, the company was fully acquired by the German company QIAGEN. QIAGEN has world-leading innovative technologies, providing nucleic acid and protein separation, purification and processing technology. QIAGEN was listed on the Nasdaq in New York and the Frankfurt stock market at the same time in 1996. It has subsidiaries in China, Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden and the Netherlands, with more than 2,600 employees located around the world.